Measurable residual disease (MRD) status is a valuable prognostic marker in multiple myeloma (MM), but questions still remain. Speaking from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, describes how although MRD tests are critically important, perhaps their true value has not yet been determined when it comes to making decisions about patient treatment, before mentioning how several trials are currently investigating the many different ways MRD can be measured and interpreted.
MRD-guided treatment in multiple myeloma
